NCT04701307: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients with neuroendocrine tumors are eligible for Cohort 2; Patients must have had at least one prior line of systemic therapy
Exclusions: Patients who have previously received a simultaneous combination of PARP inhibitor (e.g. Lynparza/olaparib, Talzenna/talazoparib) and immune checkpoint blockade (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with symptomatic, untreated, unstable brain or leptomeningeal metastases – see trial for details

Comments are closed.

Up ↑